Switzerland, particularly Zurich, has been a leader in corneal cross-linking (CXL) research and innovation for over two decades, explained ELZA’s Medical Director, Prof. Farhad Hafezi,
DGII aktuell features ELZA Medical Director Prof. Farhad Hafezi on modern corneal cross-linking strategies.
CRST explores how artificial intelligence is improving ophthalmic diagnostics, with insights from ELZA’s Prof. Farhad Hafezi.
Prof. Farhad Hafezi, MD, PhD, FARVO is the Medical Director at The ELZA Institute, was recently interviewed by Ocular Surgery News (OSN), where he spoke about advancing CXL technology for the treatment of corneal ectasias like keratoconus. The interview covered three main topics.
Léonard Kollros is the lead Optometrist at the ELZA Institute, and this month, a paper he authored was published in the Journal Français d’Ophtalmologie. It
The 18th CXL Experts’ Meeting, led by ELZA’s CMO, Prof. Farhad Hafezi, was held last weekend in Zurich, Switzerland.
Corneal cross-linking has been shown to be a effective treatment for arresting the progression of keratoconus, and this study adds to the growing body of evidence supporting its use in patients of all ages.
This month’s issue of Ophthalmology Times Europe saw the publication of a review article, “The pathophysiology and pathomorphology of corneal ectasia” authored by Prof. Hafezi, Medical Director of the ELZA Institute, and Dr. Omid Kermani, Managing Director at Augenklinik am Neumarkt in Cologne.
Can combining corneal OCT and air puff tonometry help better diagnose the earliest stages of keratoconus? That was the question ELZA researcher, Dr. Nanji Lu,
Ophthalmology Times Europe interviewed the Medical Director of ELZA Institute, Prof. Farhad Hafezi, for this month’s cover feature story: An In-Depth Look at Corneal Ectasia.
